Quote:

---

If inferior drugs like lenzilumab hit the market first it will be an uphill battle to get into the marketplace and both patients and shareholders will suffer.

---

If our interim results are good, and the FDA insists on slow-walking us to full enrollment (390), I will have no choice but to believe that they are intentionally creating a first-to-market opportunity for Humanigen, likely due to their close relationship with Gilead.

Let's face it, if any Big Pharma therapy displayed the results we achieved with our eIND patients, leronlimab would have been approved back in June.